RegeneRx Biopharmaceuticals, Inc. is a clinical‐stage biotechnology company headquartered in Rockville, Maryland. The company specializes in the development of peptide‐based therapeutics designed to address unmet medical needs in tissue repair, inflammation and degenerative diseases. Its drug discovery platform centers on analogs of Thymosin Beta‐4 (Tb4), a naturally occurring peptide that plays a key role in wound healing, cell migration and repair mechanisms.
The company’s lead product candidate, RGN-259, is a topical formulation of Tb4 that has advanced through Phase II clinical trials for the treatment of ocular surface disorders, including neurotrophic keratitis and dry eye syndrome. RegeneRx is also exploring pipeline candidates such as RGN-352, an intravenous formulation targeting cardiac and central nervous system injuries. These programs leverage preclinical data demonstrating the peptides’ ability to promote angiogenesis, reduce inflammation and stimulate tissue regeneration.
RegeneRx maintains a global patent portfolio covering its proprietary peptide technology, with granted patents in the United States, Europe, Japan and other jurisdictions. The company engages in collaborations and licensing agreements to support preclinical development, manufacturing and potential commercialization partnerships. Since its founding in the late 1990s, RegeneRx has focused on translating its Thymosin Beta-4 platform into therapies for wound healing, fibrosis, cardiovascular injury and other indications.
AI Generated. May Contain Errors.
Free RGRX Stock Alerts